Westlake Village BioPartners — Full Portfolio
32 tracked investments · listed companies and verified rows first
Sagimet is a clinical-stage biopharmaceutical company developing therapies targeting fatty acid synthase (FASN) for metabolic diseases and oncology.
BiotechDigital HealthHealthtechMenlo Park, US
Rekha Hemrajani(Executive Officer)inMerdad Parsey(Executive Officer, Director)inDavid Happel(Chief Executive Officer & Director)Andreas Grauer(Chief Medical Officer)inThierry Chauche(Chief Financial Officer)inMarie O'Farrell(Chief Scientific Officer)in
Board seatBeth Seidenberg· per SEC Form D · $80M raise · filed Jan 2021
Co-investorsAltium CapitalHM Venture PartnersKleiner PerkinsNew Enterprise Associates (NEA)
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)inMark Bradley(Chief Development Officer)inKolbot By(SVP, Head of Technical Operations)inJack Danilkowicz(Chief Commercial Officer)inJörn Drappa(Chief Medical Officer)inDavid M Goldstein(Chief Scientific Officer)in
Co-investorsForesite CapitalNextech InvestOrbiMedSamsara BioCapitalSR One Capital ManagementvenBio Partners+1 more
Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset.
BiotechEmeryville, US
Warner Biddle(Chief Executive Officer)inBrian Kotzin(Director)Ian Clark(Director)Ryan Jones(Executive Officer)Karen Walker(Executive Officer)Peter Maag(Executive Officer, Director)in
Co-investorsBain Capital Life SciencesVida VenturesGilead SciencesKleiner PerkinsOxford Finance LLCRTW Investments L.P.+1 more
Capsida Biotherapeutics develops engineered gene therapies for rare and common neurological and ocular diseases using an AAV capsid platform that enables improved brain and retinal delivery compared to naturally occurring capsids.
BiotechDeep TechDigital HealthMedical Devices
Viviana GradinaruNick Goeden, Ph.D.(Co-founder)Nicholas Flytzanis(Co-founder)in
Co-investorsVersant Ventures
Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.
BiotechHealthtechBoulder, US
Joey Azofeifa(Founder)inLaura Norris(Executive Officer, Director)inTimothy Read(Executive Officer, Director)Eric Martin(Executive Officer)in
BoardAmit Mehta(Director)
Board seatDavid AllisonMira Chaurushiya· per SEC Form D · $35.3M raise · filed Nov 2025
Co-investorsFifty YearsFundersClubTau VenturesvenBio PartnersY CombinatorAlamo Angels+3 more
Arsenal Biosciences is a clinical-stage company developing programmable cell therapies to treat solid tumors.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Ken Drazan(Founder)James Ahlers(Executive Officer)Irene Pleasure(Executive Officer)Margaret Nibbi(Executive Officer)
BoardValentin Barsan(Director)Sean Parker(Director)
Board seatBeth Seidenberg· per SEC Form D
Co-investorsARCH Venture PartnersHitachi VenturesKleiner PerkinsOUP (Osage University Partners)SoftBank Vision Fund
Impel Pharmaceuticals develops therapies for diseases with high unmet medical needs by pairing established drugs with its proprietary upper-nasal drug delivery technology.
BiotechHealthtechMedical DevicesSeattle, US
John D. Hoekman(Executive Officer, Director)in
BoardMichael Hite(Director)Stewart Parker(Director)
Board seatDavid Allison· per SEC Form D · $1.9M raise · filed Apr 2021
Co-investors5AM VenturesB Capital GroupvenBio Global StrategicvenBio Partners
.jpeg){kind=logo}
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk.
BiotechHealthtechMedical DevicesThousand Oaks, US
Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)
BoardJim Tananbaum(Director)inDeborah Palestrant(Director)inKevin Raidy(Director)
Board seatBeth Seidenberg· per SEC Form D
Co-investorsAccess BiotechnologyForesite CapitalKern Capital, LLCSanofi Ventures5AM Ventures
Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders.
BiotechHealthtechWoburn, US
Cyril De Colle(Founder)inCYRIL DE COLLE(Executive Officer, Director)inJAMES DETORE(Executive Officer)JAMES O'MARA(Executive Officer, Director)inPAUL ROGERS(Executive Officer)in
Board seatDavid Allison· per SEC Form D
Co-investors5AM VenturesOrbiMedSamsara BioCapitalvenBio PartnersVivo CapitalRTW Investments L.P.+1 more
Soteria Biotherapeutics develops protein-based biotherapeutics and small molecules using its LITE Switch technology platform for drug discovery and development across oncology, immune-oncology, and inflammatory disease indications.
BiotechDeep TechHealthtechMedical DevicesWellness & FitnessSan Francisco, US
Zachary B. Hill(SVP, Chief Scientific Officer and Co-founder)Jim Wells(Co-founder, Scientific Advisory Board Chair)Kristine M Ball(Executive Officer, Director)inZachary Hill(Executive Officer, Director)in
BoardNisha Marathe(Director)
Board seatDavid Allison· per SEC Form D
Co-investors5AM VenturesNovartis Venture FundRoche Venture FundVersant VenturesBioGeneration Ventures
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)inNancy Stagliano(Director)inMichelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)Scott Robertson(Executive Officer)inGary Patou(Executive Officer)in
Board seatBeth Seidenberg· per SEC Form D · $125M raise · filed Oct 2025
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesSofinnova VenturesAgent Capital+9 more
3T Biosciences develops TCR-based immunotherapies for cancer using a proprietary platform that combines machine-learning algorithms with immunological research to identify and validate T cell receptor targets.
AI & Machine LearningBiotechHealthtechMedical DevicesSouth San Francisco, US
K. Christopher GarciaMarvin Gee(Founder)in
Co-investorsAsset Management CompanyCRV (Charles River Ventures)Menlo VenturesOS FundStarlight Ventures
AllRock Bio is a drug development company advancing novel therapies for pulmonary hypertension, interstitial lung diseases, and other fibrotic conditions.
BiotechNatick, US
Catherine Pearce(CEO & Founder)inDHSc(Founder)Justin R Thompson(Founder)in
Co-investorsVersant VenturesWestlake BioPartners
Borealis develops RNA medicines to treat kidney diseases.
BiotechDigital Health
Co-investorsVersant Ventures
Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Adam Rosenthal(Co-founder and former CEO; Director)inQuehuong (Kathy) Dong, Pharm.D.(Executive Officer, Director)Kathy Dong(President, Chief Executive Officer and Director)in
BoardBeth Seidenberg, M.D.(Director)Thomas Geninatti, Ph.D.(Director)Carl Gordon, Ph.D.(Director)
Co-investorsOrbiMedRA CapitalKleiner PerkinsNVIDIA
BiotechSan Diego, US
Kevin Forrest, Ph.D.(Executive Officer, Director)
BoardClare Ozawa, Ph.D.(Director)Beth Seidenberg, M.D.(Director)
Co-investorsKleiner PerkinsOsage University PartnersVersant Ventures
Magnetic Particle Imaging (MPI) is an imaging technology that detects iron oxide nanoparticle tracers using time-varying magnetic fields to create medical images with high contrast and sensitivity.
Deep TechHealthtechMedical Devices
Co-investors5AM VenturesEvolution VC PartnersInnolinks VenturesSand Hill AngelsShangBay Capital LLCCelesta Capital
Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease.
AI & Machine LearningBiotechDeep TechDigital HealthSouth San Francisco, US
Nancy Stagliano(CEO)in
Co-investorsKleiner PerkinsSoftBank GroupSoftBank Vision FundACORN BIOVENTURESCowen Healthcare InvestmentsHBM Partners+1 more
Oorja Bio is a biotechnology company developing therapies focused on fibrotic disease, aiming to repair, reverse, and remodel fibrosis.
BiotechHealthtech
Sujay Kango(Chief Executive Officer & Founder)inJanethe Pena(Chief Medical Officer & Founder)inConnie Coulomb(Chief Business Officer & Founder)in
Co-investorsAndreessen HorowitzKleiner PerkinsWestlake BioPartners
BiotechMenlo Park, US
Brett Ewald(Executive Officer)inUmesh Gangadharmath(Executive Officer)inIstvan Molnar(Executive Officer)inYunfei Zhu(Executive Officer)Ana Kusnetzow(Executive Officer)inScott Struthers(Director)
Co-investorsDCVC (Data Collective)Frazier Life Sciences5AM VenturesDCVC BioFrazier Healthcare Partners
Recludix Pharma operates a drug discovery platform that combines custom DNA-encoded libraries (DELs), massively parallel structure-activity relationship analysis, structure-based design, and a family-wide SH2 domain screening panel.
AI & Machine LearningBiotechDeep TechHealthtechSan Diego, US
Nancy Whiting(CEO)in
Co-investorsAccess BiotechnologyNew Enterprise Associates (NEA)
Vedana Therapeutics develops next-generation biologic medicines for migraine prevention, targeting PACAP and CGRP-independent pathways to address unmet needs in patients inadequately controlled by current therapies.
BiotechHealthtechMedical Devices
Co-investorsCanaan Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AllRockArsenalCinCor PharmaElectraExpansion TherapeuticsKateLatigoStarTmunityVega
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.